Science & Technology

CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer

Department of Health and Human Services — National Institutes of Health

Opportunity #: 1R44CA310518-01

Award Ceiling

$1.4M

Award Floor

$1.4M

Close Date

Aug 31, 2027

534 days left

Total Funding

$1.4M

Expected Awards

Posted Date

Sep 17, 2025

Cost Sharing Required

Grants.gov ID

sbir-1R44CA310518-01

Description

SBIR Phase Phase II award: "CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer" awarded to EMBIOSYS INC. in North Andover, Massachusetts. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,379,442. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.

Eligible Applicants

Small businesses, Socially/economically disadvantaged

Apply on Grants.gov

Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.

View on Grants.gov

Disclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.